Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view

Autor: Borja Quiroga, Antonio de Santos, David Sapiencia, Yamila Saharaui, Vicente Álvarez-chiva

Publikováno v: Nefrología (English Edition), Vol 39, Iss 6, Pp 646-652 (2019)

Introduction: Sacubitril/valsartan reduces cardiovascular morbidity and mortality in patients with systolic dysfunction (SD). The aim of the present study was to assess the evolution of chronic kidney disease (CKD) patients after initiating sacubitri

Externí odkaz: https://doaj.org/article/d55c67f8a4da48f498acfd6efb9840ee

Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study

Autor: Patricia Muñoz Ramos, Yohana Gil Giraldo, Vicente Álvarez-Chiva, David Arroyo, Cristina Sango Merino, Francesc Moncho Francés, Javier Ocaña, Javier Reque, Emilio Sánchez-Álvarez, José Luis Górriz, Borja Quiroga

Publikováno v: Metabolites, Vol 11, Iss 11, p 760 (2021)

Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect on renal fun

Externí odkaz: https://doaj.org/article/75a018c902c14923a7af7257c93f444c

Experiencia clínica con sacubitrilo/valsartán en pacientes con insuficiencia renal: la visión del nefrólogo

Autor: Yamila Saharaui, Vicente Álvarez-Chiva, David Sapiencia, Antonio de Santos, Borja Quiroga

Publikováno v: Nefrología, Vol 39, Iss 6, Pp 646-652 (2019)

Resumen: Antecedentes y objetivo: Sacubitrilo/valsartán ha demostrado ser eficaz en la reducción de la morbimortalidad cardiovascular en los pacientes con disfunción sistólica. El objetivo del presente estudio fue analizar la evolución de pacien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65d896147f61d2c43c3228b923da656
https://doi.org/10.1016/j.nefro.2019.01.005

Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study

Autor: Borja Quiroga, Francesc Francés, Yohana Gil Giraldo, Emilio Sánchez-Álvarez, Vicente Álvarez-Chiva, Javier Reque, David Arroyo, Javier Ocaña, José Luis Górriz, Cristina Sango Merino, Patricia Muñoz Ramos

Publikováno v: Metabolites
Volume 11
Issue 11
Metabolites, Vol 11, Iss 760, p 760 (2021)
Muñoz Ramos, Patricia Gil Giraldo, Yohana Álvarez Chiva, Vicente Arroyo, David Sango Merino, Cristina Moncho, Francesc Ocaña, Javier Reque, Javier Sánchez Álvarez, Emilio Górriz Teruel, Jose Luis Quiroga, Borja 2021 Proteinuria-lowering effects of proprotein convertase subtilisin/kexin type 9 inhibitors in chronic kidney disease patients : a real-world multicentric study Metabolites
RODERIC. Repositorio Institucional de la Universitat de Valéncia
instname

Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect on renal fun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::600a3d08ca5740de9b1eefbd80b44ca4
https://doi.org/10.3390/metabo11110760

Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease

Autor: Borja Quiroga, Patricia Muñoz Ramos, Vicente Álvarez Chiva

Publikováno v: Nefrología (English Edition), Vol 40, Iss 5, Pp 499-505 (2020)

The use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has changed the clinical practice of dyslipidemia and their effects in cardiovascular events. Nowadays two active principles have been commercialized (evolocumab and alircum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd7855161b339ecd8e235b830f7be385
https://pubmed.ncbi.nlm.nih.gov/32682569